These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 29314183)

  • 21. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
    Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
    Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population pharmacokinetic evaluation of a fully human IgG monoclonal antibody in patients with inflammatory diseases.
    Tabrizi M; Wang B; Lu H; Huang S; Bell G; Schwab G; Roskos L
    Inflamm Allergy Drug Targets; 2010 Sep; 9(4):229-37. PubMed ID: 20860546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eculizumab dose tapering should take into account the nonlinearity of its pharmacokinetics.
    Le Tilly O; Gatault P; Semlali S; Sberro-Soussan R; Passot C; Bertrand D; Desvignes C; Caillard S; Paintaud G; Halimi JM; Ternant D
    Br J Clin Pharmacol; 2024 May; 90(5):1312-1321. PubMed ID: 38373846
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial.
    Ng CM; Bruno R; Combs D; Davies B
    J Clin Pharmacol; 2005 Jul; 45(7):792-801. PubMed ID: 15951469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.
    Zhou H; Jang H; Fleischmann RM; Bouman-Thio E; Xu Z; Marini JC; Pendley C; Jiao Q; Shankar G; Marciniak SJ; Cohen SB; Rahman MU; Baker D; Mascelli MA; Davis HM; Everitt DE
    J Clin Pharmacol; 2007 Mar; 47(3):383-96. PubMed ID: 17322150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain.
    Jonsson EN; Xie R; Marshall SF; Arends RH
    Br J Clin Pharmacol; 2016 Apr; 81(4):688-99. PubMed ID: 26613544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial.
    Mallalieu NL; Wimalasundera S; Hsu JC; Douglass W; Wells C; Penades IC; Cuttica R; Huppertz HI; Joos R; Kimura Y; Milojevic D; Rosenkranz M; Schikler K; Constantin T; Wouters C
    Pediatr Rheumatol Online J; 2019 Aug; 17(1):57. PubMed ID: 31438986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population Pharmacokinetics of ABT-806, an Investigational Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody, in Advanced Solid Tumor Types Likely to Either Over-Express Wild-Type EGFR or Express Variant III Mutant EGFR.
    Sharma S; Mittapalli RK; Holen KD; Xiong H
    Clin Pharmacokinet; 2015 Oct; 54(10):1071-81. PubMed ID: 25761639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics and C-reactive protein modelling of anti-interleukin-6 antibody (PF-04236921) in healthy volunteers and patients with autoimmune disease.
    Li C; Shoji S; Beebe J
    Br J Clin Pharmacol; 2018 Sep; 84(9):2059-2074. PubMed ID: 29776017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Confirmatory Population Pharmacokinetic Analysis for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin-6, in Patients With Moderately to Severely Active Rheumatoid Arthritis.
    Xu Y; Hu C; Zhuang Y; Hsu B; Xu Z; Zhou H
    J Clin Pharmacol; 2018 Jul; 58(7):939-951. PubMed ID: 29578578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population Pharmacokinetics and Exposure-Response Relationship of Intravenous and Subcutaneous Abatacept in Patients With Rheumatoid Arthritis.
    Li X; Roy A; Murthy B
    J Clin Pharmacol; 2019 Feb; 59(2):245-257. PubMed ID: 30229926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A population pharmacokinetic model for low-dose methotrexate and its polyglutamated metabolites in red blood cells.
    Korell J; Stamp LK; Barclay ML; Dalrymple JM; Drake J; Zhang M; Duffull SB
    Clin Pharmacokinet; 2013 Jun; 52(6):475-85. PubMed ID: 23483363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Covariate effects and population pharmacokinetic analysis of the anti-FGFR2b antibody bemarituzumab in patients from phase 1 to phase 2 trials.
    Xiang H; Liu L; Gao Y; Ahene A; Collins H
    Cancer Chemother Pharmacol; 2021 Nov; 88(5):899-910. PubMed ID: 34383128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
    Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
    Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study).
    Ohta S; Tsuru T; Terao K; Mogi S; Suzaki M; Shono E; Ishida Y; Tarumi E; Imai M
    J Clin Pharmacol; 2014 Jan; 54(1):109-19. PubMed ID: 24115082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis.
    Bannwarth B; Péhourcq F; Schaeverbeke T; Dehais J
    Clin Pharmacokinet; 1996 Mar; 30(3):194-210. PubMed ID: 8882301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Local versus systemic anti-tumour necrosis factor-α effects of adalimumab in rheumatoid arthritis: pharmacokinetic modelling analysis of interaction between a soluble target and a drug.
    Stepensky D
    Clin Pharmacokinet; 2012 Jul; 51(7):443-55. PubMed ID: 22540283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patterns of use and dosing of tocilizumab in the treatment of patients with rheumatoid arthritis in routine clinical practice: the ACT-LIFE study.
    Balsa A; Tovar Beltrán JV; Cáliz Cáliz R; Mateo Bernardo I; García-Vicuña R; Rodríguez-Gómez M; Belmonte Serrano MA; Marras C; Loza Cortina E; Pérez-Pampin E; Vila V
    Rheumatol Int; 2015 Sep; 35(9):1525-34. PubMed ID: 25773655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis.
    Roy A; Mould DR; Wang XF; Tay L; Raymond R; Pfister M
    J Clin Pharmacol; 2007 Nov; 47(11):1408-20. PubMed ID: 17962428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Modeling of Weight-Based Intravenous Reslizumab Dosing.
    Passarell J; Jaworowicz D; Ludwig E; Rabinovich-Guilatt L; Cox DS; Levi M; Garin M; Fiedler-Kelly J; Bond M
    J Clin Pharmacol; 2020 Aug; 60(8):1039-1050. PubMed ID: 32333684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.